MedPath
Found 10 clinical trials|View Analysis
Sort by:

FIH Trial of VERT-002 in Patients with Locally Advanced or Metastatic Solid Tumors with MET Alterations

Phase 1
Recruiting
Conditions
Solid Tumor
MET Alteration
Interventions
Drug: VERT-002
First Posted Date
2024-11-01
Last Posted Date
2024-12-10
Lead Sponsor
Pierre Fabre Medicament
Target Recruit Count
140
Registration Number
NCT06669117
Locations
🇺🇸

Gabrail Cancer Research Center, Canton, Ohio, United States

🇺🇸

Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee, United States

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Phase 2
Withdrawn
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2022-10-05
Last Posted Date
2024-06-17
Lead Sponsor
Timothy Burns, MD, PHD
Registration Number
NCT05567055

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)

Completed
Conditions
METex14 Mutations
MET Alterations
Non Small Cell Lung Cancer
First Posted Date
2021-12-13
Last Posted Date
2023-01-06
Lead Sponsor
Intergroupe Francophone de Cancerologie Thoracique
Target Recruit Count
182
Registration Number
NCT05154344
Locations
🇫🇷

CHU, Tours, France

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

Phase 1
Withdrawn
Conditions
Brain Tumor
Interventions
First Posted Date
2021-11-16
Last Posted Date
2024-04-17
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT05120960

Tepotinib in Solid Tumors Harboring MET Alterations

Phase 2
Recruiting
Conditions
Solid Tumor
MET Exon 14 Skipping Mutation
MET Amplification
Interventions
First Posted Date
2020-12-01
Last Posted Date
2020-12-02
Lead Sponsor
Chungbuk National University Hospital
Target Recruit Count
100
Registration Number
NCT04647838
Locations
🇰🇷

Konyang University Hospital, Daejeon, Korea, Republic of

🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of

and more 19 locations

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Phase 1
Active, not recruiting
Conditions
Advanced Solid Tumor
MET Gene Alterations
Metastatic Solid Tumors
Interventions
Drug: elzovantinib (TPX-0022)
First Posted Date
2019-06-21
Last Posted Date
2024-12-20
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
95
Registration Number
NCT03993873
Locations
🇺🇸

Local Institution - 2102, La Jolla, California, United States

🇺🇸

Local Institution - 2108, Orange, California, United States

🇺🇸

Local Institution - 2105, Denver, Colorado, United States

and more 21 locations

A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumor
Interventions
Drug: Gumarontinib Tablets
First Posted Date
2018-03-07
Last Posted Date
2024-11-01
Lead Sponsor
Haihe Biopharma Co., Ltd.
Target Recruit Count
177
Registration Number
NCT03457532
Locations
🇨🇳

Shanghai East hospital, Shanghai, China

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Phase 2
Active, not recruiting
Conditions
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
Lung Adenocarcinoma Stage IIIB/IV
Interventions
First Posted Date
2016-08-12
Last Posted Date
2024-08-30
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Target Recruit Count
337
Registration Number
NCT02864992
Locations
🇺🇸

Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States

🇺🇸

Virginia Cancer Specialists, PC, Fairfax, Virginia, United States

🇺🇸

Wenatchee Valley Hospital & Clinics - ATTN: Jay Johnson, Wenatchee, Washington, United States

and more 154 locations

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Phase 2
Completed
Conditions
Malignant Non-small Cell Neoplasm of Lung Stage IV
Interventions
First Posted Date
2016-04-25
Last Posted Date
2022-03-14
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
20
Registration Number
NCT02750215
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of DCC-2701 in Participants With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Metastatic Solid Tumors
Cancers With MET Genomic Alterations
Cancers With TRK Genomic Alterations
Locally Advanced Tumors
Interventions
Drug: DCC-2701 tablet
First Posted Date
2014-08-29
Last Posted Date
2018-02-01
Lead Sponsor
Deciphera Pharmaceuticals, LLC
Target Recruit Count
44
Registration Number
NCT02228811
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath